Page last updated: 2024-10-16

quinacrine and Porphyria Cutanea Tarda

quinacrine has been researched along with Porphyria Cutanea Tarda in 1 studies

Quinacrine: An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2.
quinacrine : A member of the class of acridines that is acridine substituted by a chloro group at position 6, a methoxy group at position 2 and a [5-(diethylamino)pentan-2-yl]nitrilo group at position 9.

Porphyria Cutanea Tarda: An autosomal dominant or acquired porphyria due to a deficiency of UROPORPHYRINOGEN DECARBOXYLASE in the LIVER. It is characterized by photosensitivity and cutaneous lesions with little or no neurologic symptoms. Type I is the acquired form and is strongly associated with liver diseases and hepatic toxicities caused by alcohol or estrogenic steroids. Type II is the familial form.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
ILIN, II1

Other Studies

1 other study available for quinacrine and Porphyria Cutanea Tarda

ArticleYear
[THE TREATMENT OF PORPHYRIA CUTANEA TARDA].
    Vestnik dermatologii i venerologii, 1963, Volume: 37

    Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Bloodletting; Calcium; Chlorides; Desensitizat

1963